All the news and blogs
Business & Finance
Tech & Science
Our mobile app
Our groups in social networks
Nothing was found on your request
Why Drug Giant Teva Pharma Just Rocketed Into A Profit-Taking Zone
Teva Pharmaceutical easily beat fourth-quarter expectations Wednesday, sending Teva stock rocketing to a nine-month high. Guidance was likely in line when accounting for a reporting change. The post
IBD Rating Upgrades: AmerisourceBergen Flashes Improved Relative Price Strength
AmerisourceBergen shows improving price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: AmerisourceBergen Flashes Improved Relative Price Strength
CEO Q&A: Here's What You Need To Know About The New Bristol-Myers
Pharmaceutical company Bristol-Myers is remaking itself in the wake of its Celgene merger, says CEO Giovanni Caforio. BMY stock has run up 54% after hitting a low point six months ago. The post CEO
Analysis: Major Pharmaceuticals' January Drug Price Hikes Were Smallest in at Least 6 Years
Analysts at investment bank Raymond James theorize that the trend will continue.
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers
Regulators are trying their best to help encourage competition, particularly in the biosimilars market.
Insurers Take Aim at Big Pharma. This Small-Cap Stock Stands to Win.
Drug manufacturer Catalent is ready to capitalize on the drug industry's shifting norms.
Novartis Edges Higher Into Buy Zone Even As Generic Drugs Struggle
Novartis stock edged higher into a buy zone Wednesday after the Swiss pharmaceutical company topped fourth-quarter earnings views, though sales were slightly lighter than analysts expected. The post
Is Mylan Stock a Buy?
Mylan’s planned combination with Upjohn is a bright spot for investors, but the difficulties of the U.S. generic-drug market remain a potential obstacle.
Why Long-Term Investors Should Avoid TEVA Stock Like the Plague
Strapped with debt and battling legal controversies right and left, Teva’s best days could very well be behind it.
The Top 3 Contrarian Stocks to Buy in 2020
Following declines of at least 30% in 2019, these stocks now look to be bounce-back candidates.
California Governor Gavin Newsom Proposes State-Run Prescription Drug Label
The idea is among a set of proposals aimed at cooling healthcare costs in the state.
CVS, Walgreens, And Rite Aid Sue Doctors In Latest Move In Federal Opioid Case
The drugstores allege it was the doctors who prescribed the pills who should shoulder the culpability for the opioid crisis.
Multi-Billion Dollar Opioid Litigation Targets Drug Companies, Drugstores, and Maybe Doctors
Several companies might have to pay out $48 billion or more.
Why Antares Pharma's Sliding 10% Today
Investors are locking in gains in this fast-growing drugmaker.
My Top Portfolio Holdings for 2020
These four stocks will hopefully be bringing home the bacon in the new year.
3 Buffett Stocks That Will Make You Richer in 2020
Feel free to ride Warren Buffett's coattails to profits in the upcoming year.
Save Yourself the Migraine and Buy This 1 Pharma Stock Now
Late-stage clinical trial results provide a chance for investors to gain significant upside from this developer of drugs combating neurological diseases.
Opioid Epidemic: Feds Reportedly Launch Criminal Probe Into Drugmakers
Shares of pharmaceuticals companies Teva, Amneal and Mallinckrodt slumped Tuesday on a report that federal prosecutors have opened a criminal investigation into the opioid epidemic. The post Opioid
An In-Depth Breakdown of Warren Buffett's Portfolio
A detailed sector-by-sector look at what the Oracle of Omaha has invested in.
Here's Why Corcept Therapeutics Stock Hit the Bricks Today
The company's fight to keep generic competition at bay took a turn for the worse.